1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical and demographic data
Patient No. Sex Age (yr) Clinical Phenotype EDSS Disease Duration (yr) Disease-Modifying Treatment
1 Female 60 RR 1.5 11 Dimethyl fumarate
2 Female 66 Progressive 7 28 None
3 Male 56 Progressive 6 24 None
4 Male 47 RR 1.5 16 Daclizumab
5 Female 43 RR 2 43 None
6 Female 64 RR 1.5 9 None
7 Female 55 RR 1.5 2 Interferon β-1a
8 Male 36 RR 1 7 Glatiramer acetate
9 Male 61 Progressive 6.5 40 None
10 Female 51 Progressive 6.5 24 None
11 Female 35 RR 1 4 Dimethyl fumarate
12 Female 36 RR 2.5 18 Glatiramer acetate
13 Male 38 RR 0 1 None
14 Female 28 RR 1.5 1 None
15 Female 33 RR 2 1 None
16 Female 42 RR 2.5 10 Mycophenolate mofetil
17 Female 25 RR 2 1 Glatiramer acetate
18 Female 30 RR 1.5 8 None
19 Female 36 RR 1.5 9 Dimethyl fumarate
20 Female 71 RR 1 15 None
Note:—RR indicates relapsing-remitting.